Mabvax Therapeutics Holdings, Inc. v. Honig

CourtDistrict Court, S.D. California
DecidedOctober 4, 2019
Docket3:19-cv-00981
StatusUnknown

This text of Mabvax Therapeutics Holdings, Inc. v. Honig (Mabvax Therapeutics Holdings, Inc. v. Honig) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mabvax Therapeutics Holdings, Inc. v. Honig, (S.D. Cal. 2019).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 SOUTHERN DISTRICT OF CALIFORNIA 6 7 MABVAX THERAPEUTICS Case No.: 19-cv-981-WQH-MSB HOLDINGS, INC., a Delaware 8 Corporation, ORDER 9 Plaintiff, 10 v. 11 BARRY HONIG, et al., 12 Defendants. 13 HAYES, Judge: 14 The matter before the Court is the Motion to Remand filed by Plaintiff MabVax 15 Therapeutics Holdings, Inc. (ECF No. 21). 16 I. BACKGROUND 17 On April 8, 2019, Plaintiff filed a Complaint in the Superior Court of the State of 18 California for the County of San Diego against Defendants. (ECF No. 1-2). Plaintiff is a 19 clinical-stage biotechnology company that develops cancer treatments. Id. ¶ 1. Plaintiff 20 alleges that Defendants, “a group of market manipulators” led by Defendant Barry Honig, 21 accumulated a controlling position in Plaintiff’s stock. Id. ¶ 3. Plaintiff alleges that 22 Defendants “pretended they sought legitimate returns” by investing in Plaintiff, but they 23 really sought to manipulate Plaintiff. Id. Plaintiff alleges that Defendants “defrauded 24 [Plaintiff] through illicit transactions for their enormous profit to the detriment of 25 [Plaintiff].” Id. Plaintiff alleges that, among other things, Defendants caused Plaintiff to 26 issue Defendants “tens of millions of dollars’ worth of common stock;” cut Plaintiff off 27 from legitimate investors; caused Plaintiff to be subjected to a SEC investigation; forced 28 1 Plaintiff to “publicly disclaim reliance on past financial statements rendered inaccurate by 2 Defendants;” and caused Plaintiff to be delisted from trading on Nasdaq. Id. 3 Plaintiff brings state law claims against Defendants for 1) market manipulation in 4 violation of section 25400 of the California Corporations Code; 2) unlawful business 5 practices in violation of section 17200 of the California Business & Professions Code; 3) 6 fraud and deceit in violation of sections 1709 and 1710 of the California Civil Code and 7 California common law; 4) fraudulent concealment in violation of section 1710 of the 8 California Civil Code and California common law; 5) constructive fraud in violation of 9 section 1573 of the California Civil Code and California common law; 6) negligent 10 misrepresentation in violation of section 1710 of the California Civil Code and California 11 common law; 7) tortious interference with prospective economic advantage; 8) breach of 12 fiduciary duty; and 9) restitution for unjust enrichment. (ECF No. 1-2). Plaintiff seeks 13 damages, including punitive damages, attorneys’ fees, costs, and pre- and post-judgment 14 interest. Plaintiff requests that the Court require Defendants “to make a full disclosure and 15 accounting of their interests and transactions in Plaintiff’s securities” and seeks “other legal 16 and equitable relief as [the Court] may deem proper.” Id. at 42. 17 On March 21, 2019, Plaintiff filed a petition for relief under chapter 11 of title 11 of 18 the United States Code in the United States Bankruptcy Court for the District of Delaware. 19 (ECF No. 21-1 at 9). 20 On May 24, 2019, Defendants OPKO Health, Inc., Steven Rubin, Philip Frost, and 21 Frost Gamma Investments Trust (collectively, the “OPKO Defendants”) removed 22 Plaintiff’s California state court action to this Court “[p]ursuant to 28 U.S.C. §§ 1334, 1441 23 and 1452.” (ECF No. 1 at 3). The OPKO Defendants removed this action on the grounds 24 that this Court has jurisdiction based on this action’s relationship to Plaintiff’s bankruptcy 25 action. (ECF No. 1 at 5). The Notice of Removal states that the claims brought by Plaintiff 26 “represent an asset of the estate” in Plaintiff’s bankruptcy action. Any recovery in this 27 action “will have an effect on MabVax’s bankruptcy estate as it will inure to the benefit of 28 creditors.” Id. The OPKO Defendants assert that this Court, therefore, has jurisdiction 1 under 28 U.S.C. § 1334, because this action is “related to” Plaintiff’s bankruptcy action. 2 Id. at 4. 3 On May 31, 2019, Defendants Robert Prag, The Del Mar Consulting Group, Inc., 4 and The Del Mar Consulting Group, Inc. Retirement Plan Trust (collectively, the “Del Mar 5 Defendants”) filed an Answer. (ECF No. 7). 6 On June 13, 2019, Plaintiff filed a Motion to Remand this action to state court. (ECF 7 No. 21). Plaintiff contends that the Court should exercise its discretion to remand this 8 action pursuant to 28 U.S.C. § 1452(b). Plaintiff contends that each of the 14 factors courts 9 may consider pursuant to § 1452(b) weigh in favor of remand. Id. at 11. On July 1, 2019, 10 the OPKO Defendants filed a Response in opposition to Plaintiff’s Motion to Remand. 11 (ECF No. 48). The OPKO Defendants contend that this Court has subject matter 12 jurisdiction pursuant to § 1452, and the 14 factors weigh in favor of maintaining this action 13 in federal court. (ECF No. 48 at 5-6). 14 On July 1, 2019, Defendants Michael Brausner, Grander Holdings, Inc., and Grander 15 Holdings, Inc. 401K (collectively, the “Grander Defendants”) joined the OPKO 16 Defendants’ Response. (ECF No. 51). On July 2, 2019, Defendants Honig, GRQ 17 Consultants, Inc., GRQ Consultants, Inc. 401K, GRQ Consultants, Inc. Roth 401K FBO 18 Barry Honig, GRQ Consultants, Inc. Roth 401K FBO Renee Honig, Barry and Renee 19 Honig Charitable Foundation, Inc., Southern Biotech, Inc. (collectively, the “GRQ 20 Defendants”) joined the OPKO Defendants’ Response. (ECF No. 55). Defendants John 21 O’Rourke, III and ATG Capital, LLC also Joined the OPKO Defendants’ Response.1 (ECF 22 No. 56). On July 8, 2019, Plaintiff filed a Reply. (ECF No. 65). 23 II. LEGAL STANDARD 24 “Federal courts are courts of limited jurisdiction.” Kokkonen v. Guardian Life Ins. 25 Co. of Am., 511 U.S. 375, 377 (1994). The party seeking to remove a case from state court 26

27 1 The Court will, hereinafter, refer to all Defendants that filed or joined the OPKO Defendants’ Response 28 1 to federal court “always has the burden of establishing that removal is proper.” Gaus v. 2 Miles, Inc., 980 F.2d 564, 566 (9th Cir. 1992). The propriety of removal may be “tested in 3 the federal court, either on a motion by a party to remand, or by the court on its own 4 motion.” Libhart v. Santa Monica Dairy Co., 592 F.2d 1062, 1065 (9th Cir. 1979). There 5 is a “strong presumption against removal.” Gaus v. Miles, Inc., 980 F.2d 564, 566 (9th Cir. 6 1992). The removal statutes are strictly construed against removal; “any doubt about the 7 right of removal requires resolution in favor of remand.” Moore-Thomas v. Alaska Airlines, 8 Inc., 553 F.3d 1241, 1244 (9th Cir. 2009). 9 28 U.S.C. § 1452 governs the removal of claims related to bankruptcy proceedings. 10 Under § 1452, “[a]ny party may remove any claim or cause of action in a civil action . . . 11 to the district court for the district where such civil action is pending, if the district court 12 has jurisdiction . . . under section 1334 of this title.” 28 U.S.C. § 1452(a).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
Moore-Thomas v. Alaska Airlines, Inc.
553 F.3d 1241 (Ninth Circuit, 2009)
In Re Sapolin Paints, Inc.
5 B.R. 412 (E.D. New York, 1980)
In Re Roman Catholic Bishop of San Diego
374 B.R. 756 (S.D. California, 2007)
Nilsen v. Neilson (In Re Cedar Funding, Inc.)
419 B.R. 807 (Ninth Circuit, 2009)
Libhart v. Santa Monica Dairy Co.
592 F.2d 1062 (Ninth Circuit, 1979)

Cite This Page — Counsel Stack

Bluebook (online)
Mabvax Therapeutics Holdings, Inc. v. Honig, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mabvax-therapeutics-holdings-inc-v-honig-casd-2019.